Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
boceprevir + peginterferon alfa-2b + ribavirin
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This is a combination antiviral regimen consisting of boceprevir, peginterferon alfa-2b, and ribavirin. It is used for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults with compensated liver disease, including cirrhosis. Boceprevir is a direct acting antiviral agent that inhibits the HCV NS3/4A serine protease, thereby preventing viral replication[3][7]. Peginterferon alfa-2b is a recombinant form of human interferon that stimulates the innate antiviral response by binding to type 1 interferon receptors and activating the JAK/STAT pathway[6]. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity; it enhances viral clearance when combined with interferons. This triple therapy was previously standard-of-care but has largely been replaced by newer direct acting antivirals due to improved efficacy and safety profiles[3][5].
- Brand names
- Victrelis + PegIntron + Copegus
- Other names
- peginterferon alfa-2b + ribavirin + boceprevir
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on boceprevir + peginterferon alfa-2b + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on boceprevir + peginterferon alfa-2b + ribavirin.